A study of ESG401 for advanced HR+/HER2- breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a new medicine called ESG401 for people with a common type of breast cancer (HR+/HER2-) that has spread and hasn't responded to at least one chemotherapy. The goal is to see if it works better than standard chemotherapy options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- Your breast cancer must be HR-positive and HER2-negative, and it has spread to other parts of the body (locally advanced or metastatic).
- You have already tried at least one type of chemotherapy for the metastatic cancer, but it stopped working.
- You have at least one tumor that can be measured on a scan.
- You are well enough to do light activities (ECOG score 0 or 1) and expected to live at least 3 more months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called SKB264 for people with a common type of breast cancer (HR+/HER2-) that has spread or come back and has not responded to at least one round of chemotherapy. It aims to see if this treatment can help shrink tumors or slow the disease.
This trial tests a combination of two drugs—eribulin (a chemotherapy) and sintilimab (an immunotherapy that helps your immune system attack cancer)—as a first treatment for women with advanced HER2-negative breast cancer that cannot be removed by surgery.
This study tests how well and how safely different combinations of cancer drugs work for people with metastatic or inoperable locally advanced breast cancer. It may help by finding a better treatment option and collecting information to guide future care.
This trial tests a new drug, ESG401, for people with triple-negative breast cancer that has come back or spread and cannot be removed by surgery. It compares ESG401 to standard chemotherapy options to see which works better.
This trial tests a new targeted drug (hemay022) combined with an aromatase inhibitor (a type of hormone therapy) for people with advanced breast cancer that is both hormone-receptor-positive and HER2-positive. It may be an option if you've already tried trastuzumab or a similar treatment and it stopped working.
This trial tests a new drug called ES2B-C001, with or without an adjuvant, to see if it is safe for people with HER2-positive breast cancer that has spread and has not responded to previous treatments.
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.